Equities

Redwood Pharma AB

Redwood Pharma AB

Actions
  • Price (SEK)0.808
  • Today's Change-0.138 / -14.59%
  • Shares traded117.76k
  • 1 Year change-96.97%
  • Beta1.3804
Data delayed at least 15 minutes, as of May 02 2024 17:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Redwood Pharma AB is a Sweden-based company, which is primarily focused on pharmaceutical industry. The Company develops IntelliGel, a patented hydrogel drug delivery platform technology. IntelliGel is a patented supramolecular smart drug delivery system with an ability to dissolve water-insoluble and sparingly soluble drugs, or disperse, suspend and stabilize otherwise insoluble drugs. It is an odor-free, clear and transparent hydrogel with low solid content, and forms an invisible patch when applied to a surface. The Company’s development product is focused on treatment of chronic Dry Eye Disease (DED) in post-menopausal women. It is based on a naturally occurring, endogenous molecule found in the body.

  • Revenue in SEK (TTM)0.00
  • Net income in SEK-13.60m
  • Incorporated2012
  • Employees1.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Amniotics AB (publ)0.00-30.87m10.66m6.00--0.6803-----0.0374-0.03740.000.00570.00----0.00-112.25-101.09-362.71-149.92--------1.12-16.17--------35.75------
Carbiotix AB (publ)1.47m-13.48m13.44m10.00--0.1955--9.17-0.302-0.3020.03240.38170.0586--2.36146,552.00-53.88-49.38-64.85-55.50235.45574.69-919.76-1,828.86---76.280.1384--259.56-12.04-10.02--13.64--
Aptahem AB32.00k-11.11m13.72m----0.1342--428.89-0.0497-0.04970.00010.22660.0005--0.0738---16.76-39.26-19.47-44.194,623.59---34,727.72-----10.170.0847-------25.36------
AegirBio AB99.00k-367.00m15.13m1.00--1.69--152.82-24.31-24.310.00470.28950.00042.000.0207---163.02---171.79---24,398.99---370,710.10--2.53-27.270.8209---87.16---292.98------
Cyxone AB0.00-22.99m19.82m4.00--0.5088-----0.1902-0.19020.000.18040.00-------47.81-66.19-53.03-72.35------------0.0216------45.87---12.69--
Redwood Pharma AB0.00-13.60m20.08m1.00--0.2971-----5.87-5.870.003.180.00----0.00-106.53-95.03-121.24-123.04-----------19.120.00-------8.78---5.11--
Circio Holding ASA121.74k-109.60m20.52m11.00------168.55-16.75-16.750.0181-12.890.0019--0.007211,181.82-172.29-46.58---53.40-----90,029.27-6,902.00---9.827.73---98.7735.4374.42------
Asarina Pharma AB (publ)0.00-12.91m21.92m----14.02-----0.5704-0.57040.000.0690.00-------113.04-61.28-150.47-71.81------------0.3902------2.79------
Lidds AB0.00-40.21m23.20m2.00--0.8346-----0.7253-0.72530.000.20370.00----0.00-184.53-46.33-274.92-51.61-------3,076.68---------100.00---9.08------
Peptonic Medical AB37.12m-42.59m23.33m38.00--0.3097--0.6285-0.0362-0.03620.03260.04910.38571.32--976,789.50-44.25-46.02-67.60-60.8543.9054.26-114.74-139.380.7771-29.320.0912---14.93149.65-15.55--14.43--
Fluicell AB3.34m-26.55m29.10m17.00--24.40--8.72-0.2201-0.22010.02820.00360.16240.68133.84196,352.90-129.20-87.55-222.48-126.0252.0772.97-795.51-650.230.5001--0.00--2.6822.18-22.90------
Data as of May 02 2024. Currency figures normalised to Redwood Pharma AB's reporting currency: Swedish Krona SEK
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.